多变量银屑病关节炎风险评估工具(PRESTO)的推导:迈向预防的一步
研究基于635例入组时无银屑病关节炎(PsA)的银屑病患者前瞻性队列,每年由风湿科医生评估是否发展为PsA,采用惩罚二项回归建立1年和5年PsA风险预测模型。1年内51例、5年内71例发展为PsA,1年模型AUC为72.3、5年模型AUC为74.9,校准图显示预测概率与观察概率合理一致。结论认为使用常规可得临床变量可在有临床意义的时间范围内以合理准确度预测PsA的发生。
要点
- 635例银屑病患者中,1年随访期内51例、5年随访期内71例发展为银屑病关节炎。
- 1年PsA风险模型纳入年轻年龄、男性、银屑病家族史、背部僵硬、甲凹陷、关节僵硬、生物制剂使用、患者整体健康和疼痛严重度,AUC 72.3。
- 5年PsA风险模型纳入晨僵、银屑病甲病变、银屑病严重度、疲劳、疼痛及系统非生物制剂或光疗使用,AUC 74.9。
核心结论
- 使用常规可得的临床变量,可在有临床意义的时间范围内以合理准确度预测银屑病患者发生PsA。
研究设计与样本
- 分析入组时无PsA的银屑病患者前瞻性队列数据,参与者每年由风湿科医生评估是否发展为PsA。
- 使用人口学、银屑病特征、合并症、用药和肌肉骨骼症状信息建立PsA预测模型,采用惩罚二项回归进行变量选择并校正银屑病病程。
- 估计1年和5年时间段的PsA发生风险,以曲线下面积(AUC)和校准图评估模型性能。
主要发现
- 635例银屑病患者中,1年随访期内51例、5年随访期内71例发展为PsA。
- 1年内发生PsA的风险与年轻年龄、男性、银屑病家族史、背部僵硬、甲凹陷、关节僵硬、生物制剂使用、患者整体健康和疼痛严重度相关(AUC 72.3)。
- 5年内发生PsA的风险与晨僵、银屑病甲病变、银屑病严重度、疲劳、疼痛以及系统非生物制剂或光疗使用相关(AUC 74.9)。
- 校准图显示预测概率与观察概率之间具有合理一致性。
关键数值与推荐
- 1年PsA风险预测模型的AUC为72.3。
- 5年PsA风险预测模型的AUC为74.9。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A simple, scalable tool that identifies psoriasis patients at high risk for developing psoriatic arthritis (PsA) could improve early diagnosis. We aimed to develop a risk prediction model for the development of PsA and to assess its performance among patients with psoriasis. METHODS: We analyzed data from a prospective cohort of psoriasis patients without PsA at enrollment. Participants were assessed annually by a rheumatologist for the development of PsA. Information about their demographics, psoriasis characteristics, comorbidities, medications, and musculoskeletal symptoms was used to develop prediction models for PsA. Penalized binary regression models were used for variable selection while adjusting for psoriasis duration. Risks of developing PsA over 1- and 5-year time periods were estimated. Model performance was assessed by the area under the curve (AUC) and calibration plots. RESULTS: Among 635 psoriasis patients, 51 and 71 developed PsA during the 1-year and 5-year follow-up periods, respectively. The risk of developing PsA within 1 year was associated with younger age, male sex, family history of psoriasis, back stiffness, nail pitting, joint stiffness, use of biologic medications, patient global health, and pain severity (AUC 72.3). The risk of developing PsA within 5 years was associated with morning stiffness, psoriatic nail lesion, psoriasis severity, fatigue, pain, and use of systemic nonbiologic medication or phototherapy (AUC 74.9). Calibration plots showed reasonable agreement between predicted and observed probabilities. CONCLUSIONS: The development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients using readily available clinical variables.
引用
- Eder L, Lee KA, Chandran V, et al. Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention. Arthritis Rheumatol. 2023. PMID: 37555242. doi:10.1002/art.42661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。